Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01857193
Title Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

progesterone-receptor positive breast cancer

estrogen-receptor positive breast cancer

Therapies

Everolimus + Exemestane + Ribociclib

Exemestane + Ribociclib

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | BEL

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
Sylvester Comprehensive Cancer Center Main Center Miami Florida 33136 United States Details
Massachusetts General Hospital Onc Dept Boston Massachusetts 02114 United States Details
Karmanos Cancer Institute Dept of Onc Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Oncology Dept. New York New York 10017 United States Details
Oregon Health and Science University SC-5 Portland Oregon 97239 United States Details
University of Texas MD Anderson Cancer Center Onc Dept Houston Texas 77030 United States Details
Northwest Medical Specialties Tacoma Washington 98405 United States Details
Novartis Investigative Site Wilrijk 2610 Belgium Details
Novartis Investigative Site Saint Herblain cedex 44805 France Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Hospitalet de LLobregat Catalunya 08907 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field